TARA Stock Analysis: Buy, Sell, or Hold?
TARA - Protara Therapeutics, Inc. Common Stock
$3.94
-0.03 (-0.76%)
âŧ
5d:
+3.14%
30d:
-3.9%
90d:
-5.29%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When TARA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TARA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TARA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: TARA is currently trading at $3.94, which is considered fair relative to its 30-day fair value range of $3.87 to $4.03.
Technical Outlook: Technically, TARA is in a strong downtrend. The price is approaching resistance at $4.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TARA scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $25.71 (+552.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TARA is in a strong downtrend. The price is approaching resistance at $4.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TARA scores 74/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $25.71 (+552.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.87 -
$4.03
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (74/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 552.6% below Wall St target ($25.71)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.87 -
$4.03
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.46
(11.8%)
Support & Resistance Levels
Support Level
$3.72
Resistance Level
$4.05
Current Trend
Strong Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.33
Wall Street Target
$25.71
(+552.6%)
Share & Embed Analysis
Last updated: September 05, 2026 2:42 PM ET
Data refreshes hourly during market hours. Next update: 3:42 PM
Data refreshes hourly during market hours. Next update: 3:42 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jacqueline Zummo
SELL
1134 shares
2026-04-08
Jacqueline Zummo
SELL
22598 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 58 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 51 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 53 HOLD |
